News

CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation. The company itself isn't changing, but its financial picture may be about to do so. That's because by year-end

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q2 2023 Earnings CallJul 20, 2023, 9:30 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Vir Biotechnology (NASDAQ: VIR) were down more than 44% as of 10:45 a.m. on Thursday after the company announced phase 2 trial results for an influenza A therapy candidate. The stock is

Over the past three years, Novavax (NASDAQ: NVAX) has lost an astonishing 92% of its value on the market. The reason for that is no secret. The biotech quickly established itself in the race to

A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and

Shares of Novavax (NASDAQ: NVAX) have been jumping in the past month, and they are up around 25% since April. There's an influx of money coming its way due to unused COVID shots in Canada, which

After a down 2022, growth stocks are making a big comeback this year. The S&P 500 Growth index is up more than 21% this year, while the S&P 500 Value index is up just a little more than 13%

Is it over yet?

After 10 rough days of almost unabated selling, shares of telecom giant AT&T (NYSE: T) finally bounced back on Wednesday, posting a gain of 7.8% through 12:25 p.m. ET and erasing

Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their

Shares of ImmunityBio (NASDAQ: IBRX) were up 10% at 11:40 a.m. ET on Wednesday. The clinical-stage biotech company focuses on cell therapies and immunotherapy platforms, including vaccines and

Shares of Lumen (NYSE: LUMN) are posting big gains in Wednesday's trading. The telecom's stock was up 16.7% as of 11:30 a.m. ET, according to data from S&P Global Market Intelligence.

Top U.S

Shares of Amarin (NASDAQ: AMRN) were sinking 22.7% as of 10:56 a.m. ET on Wednesday. The steep decline came after the drugmaker announced an organizational restructuring after the market close on

Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine. On July 6, the company announced that along

The healthcare sector is unlikely to become obsolete anytime soon, but individual companies can very much get left behind if they fail to keep up with the changing dynamics of the industry. That's

Dividend stocks can be worth investing in, even if they don't offer big yields. That's particularly the case when it comes to companies that regularly raise their payouts. Although your initial

Novartis (NYSE: NVS) enjoyed a strong rally today, as the Swiss drugmaker announced an improved revenue forecast for 2023 and a massive share repurchase program. Specifically, the drugmaker's stock

Image source: The Motley Fool.

Novartis Ag (NYSE: NVS)Q2 2023 Earnings CallJul 18, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Fool.com contributor Parkev Tatevosian compares Ford (NYSE: F) with AT&T (NYSE: T) to determine the better dividend stock to buy right now.

*Stock prices used were the afternoon prices of July 14

Shares of AT&T (NYSE: T) were falling today after Citigroup downgraded the telecom stock ahead of its earnings report next week.

The stock was down 4.3% as of 11:26 a.m. ET on Monday.

Citi analyst

With shares of Biogen (NASDAQ: BIIB) falling by 11% in the last 30 days, and by 20% in the last five years, could there be an opportunity for enterprising investors to buy the dip on this struggling

When many investors think of tech stocks, they think of high growth potential, particularly in a short amount of time. While that can happen, you don't want to invest with only that thought in mind